2022
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022, 28: 923-1049. PMID: 35963508, PMCID: PMC10200071, DOI: 10.1016/j.eprac.2022.08.002.Peer-Reviewed Original ResearchMeSH KeywordsChildDiabetes Mellitus, Type 2DyslipidemiasEndocrinologyFemaleHumansHypoglycemic AgentsInsulinPregnancyUnited StatesConceptsClinical practice guidelinesEvidence-based recommendationsPractice guidelinesGlycemic targetsDiabetes mellitusComprehensive careCare plansEvidence-based clinical practice recommendationsEndocrinology Clinical Practice GuidelineNew evidence-based recommendationsLiterature searchManagement of prediabetesDiabetes care teamDiabetic kidney diseaseClinical practice recommendationsComprehensive care planType 1 diabetesAmerican AssociationCare of personsHealth care professionalsSecondary diabetesBariatric surgeryInsulin therapyClinical evidenceKidney diseaseOnce-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care 2022, 45: 1833-1840. PMID: 35679098, PMCID: PMC9346995, DOI: 10.2337/dc21-2275.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseChildDiabetes Mellitus, Type 2ExenatideGlycated HemoglobinHumansHypoglycemic AgentsInsulinLiraglutideMetforminPeptidesVenomsConceptsType 2 diabetesEfficacy end pointWeekly exenatideAdverse eventsPlacebo groupPrimary efficacy end pointSecondary efficacy end pointsEnd pointMetformin monotherapyTreatment of youthInsulin therapyWeek 24Pediatric patientsWeekly injectionsDaily injectionsGlycated hemoglobinCurrent treatmentExenatideBody weightDiabetesLiraglutideWeeksHemoglobinTreatmentBaselineThe obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study
Levitsky LL, Drews KL, Haymond M, Glubitosi-Klug RA, Katz L, Mititelu M, Tamborlane W, Tryggestad JB, Weinstock RS, Group T. The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study. Journal Of Diabetes And Its Complications 2022, 36: 108259. PMID: 36150365, DOI: 10.1016/j.jdiacomp.2022.108259.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBiomarkersCholesterol, LDLDiabetes Mellitus, Type 2Diabetic RetinopathyHumansObesityConceptsNon-proliferative diabetic retinopathyType 2 diabetesHigh-sensitivity C-reactive proteinObesity paradoxInflammatory biomarkersHDL cholesterolLDL cholesterolInsulin-like growth factor binding protein 1Sensitivity C-reactive proteinGrowth factor binding protein 1Today StudyPresence of retinopathyRelationship of obesityC-reactive proteinPlasminogen activator inhibitor-1Tumor necrosis factor receptor 1Digital fundus photographsNecrosis factor receptor 1Activator inhibitor-1Factor receptor 1Higher BMIObese participantsRisk markersDiabetic retinopathyInterleukin-6SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretionEfficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. The Lancet Diabetes & Endocrinology 2022, 10: 341-350. PMID: 35378069, PMCID: PMC10851108, DOI: 10.1016/s2213-8587(22)00052-3.Peer-Reviewed Original ResearchConceptsType 2 diabetesPlacebo-assigned participantsPrespecified sensitivity analysisSafety of dapagliflozinPhase 3 studyBetween-group differencesAdverse eventsPrimary outcomeProtocol populationTreat analysisYoung adultsWeek double-blind periodRandomised phase 3 studyDouble-blind periodSerious adverse eventsNew safety signalsOral dapagliflozinDiabetic ketoacidosisSevere hypoglycaemiaMean ageTreatment optionsCare treatmentParallel groupSafety signalsStudy personnelYouth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseDiabetes Mellitus, Type 2Glycated HemoglobinHumansHypoglycemic AgentsInsulinMetforminTreatment FailureConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2020
Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2019
Liraglutide in Children and Teens with Type 2 Diabetes. Reply.
Tamborlane WV, Fainberg U, Barrett T. Liraglutide in Children and Teens with Type 2 Diabetes. Reply. New England Journal Of Medicine 2019, 381: 1787. PMID: 31665592, DOI: 10.1056/nejmc1912498.Peer-Reviewed Original ResearchLiraglutide in Children and Adolescents with Type 2 Diabetes
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T. Liraglutide in Children and Adolescents with Type 2 Diabetes. New England Journal Of Medicine 2019, 381: 637-646. PMID: 31034184, DOI: 10.1056/nejmoa1903822.Peer-Reviewed Original ResearchConceptsGlycated hemoglobin levelsType 2 diabetesGastrointestinal adverse eventsAdverse eventsPlasma glucose levelsHemoglobin levelsEnd pointGlycemic controlGlucose levelsMean glycated hemoglobin levelOpen-label extension periodPrimary efficacy end pointDose of liraglutideDouble-blind periodEfficacy end pointPrimary end pointSecondary end pointsBody mass indexNumber of patientsYears of ageMetformin monotherapySubcutaneous liraglutidePlacebo groupLiraglutide groupInclusion criteriaImpact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 2Glycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingProspective StudiesRetrospective StudiesConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2DegludecInternational Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care 2019, 42: 1147-1154. PMID: 30728224, PMCID: PMC6973545, DOI: 10.2337/dc18-2316.Peer-Reviewed Original ResearchMeSH KeywordsConsensusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic KetoacidosisGlucoseHumansHypoglycemic AgentsRisk ManagementSodiumSodium-Glucose Transporter 2 InhibitorsConceptsType 1 diabetesSodium-glucose cotransporter inhibitorsDiabetic ketoacidosisCotransporter inhibitorsSGLT inhibitorsNear-normal blood glucose levelsOral antidiabetes medicationsBlood glucose levelsAntidiabetes medicationsInhibitor useBlood pressureAbsolute riskMild hyperglycemiaDKA riskGlycemic variabilityConsensus reportGlucose levelsBody weightDrug AdministrationDiabetesType 1U.S. FoodMedical communityKetoacidosisInternational consensus
2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge of OnsetChildClinical Trials as TopicDiabetes Mellitus, Type 2FemaleHealth Services AccessibilityHumansMalePatient SelectionPediatricsRegistriesResearch DesignConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollmentAdolescent type 2 diabetes: Comparing the Pediatric Diabetes Consortium and Germany/Austria/Luxemburg Pediatric Diabetes Prospective registries
Klingensmith GJ, Lanzinger S, Tamborlane WV, Hofer SE, Cheng P, de Beaufort C, Gal RL, Reinehr T, Kollman C, Holl RW. Adolescent type 2 diabetes: Comparing the Pediatric Diabetes Consortium and Germany/Austria/Luxemburg Pediatric Diabetes Prospective registries. Pediatric Diabetes 2018, 19: 1156-1163. PMID: 29923263, DOI: 10.1111/pedi.12712.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildDiabetes Mellitus, Type 2EuropeFemaleHumansMalePediatricsProspective StudiesRegistriesUnited StatesConceptsDiabetes durationClinical characteristicsBody mass index SDSAdolescent type 2Onset of T2DPediatric Diabetes ConsortiumShorter diabetes durationMost recent visitType 2 diabetesYears of ageProspective registryTreatment of youthAdverse eventsDiabetes complicationsHigher HbA1cOffice visitsHigher hemoglobinUnited States databaseVs 3.2Diabetes testingType 2RegistryLaboratory dataTreatment differencesFurther studiesThe present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent usePharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
Laffel LMB, Tamborlane WV, Yver A, Simons G, Wu J, Nock V, Hobson D, Hughan KS, Kaspers S, Marquard J. Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. Diabetic Medicine 2018, 35: 1096-1104. PMID: 29655290, PMCID: PMC6099360, DOI: 10.1111/dme.13629.Peer-Reviewed Original ResearchConceptsType 2 diabetesG/24 hPharmacodynamic profileType 2Type 2 diabetes trialsSodium-glucose co-transporter-2 inhibitor empagliflozinMaximum observed plasma concentrationPlasma concentration-time curveSimilar exposure-response relationshipsDoses of empagliflozinSerious adverse eventsParallel-group studyUrinary glucose excretionSingle oral doseDrug-related eventsObserved plasma concentrationConcentration-time curveExposure-response relationshipAdjusted mean increaseAdverse eventsDiabetes (ACCORD) trialGlucose excretionInhibitor empagliflozinOral doseMean age
2017
Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes
Tamborlane WV, Polidori D, Argenti D, Di Prospero NA. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 649-655. PMID: 29271103, DOI: 10.1111/pedi.12626.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge of OnsetBrazilCanagliflozinChildDiabetes Mellitus, Type 2Dose-Response Relationship, DrugFemaleHumansHypoglycemic AgentsMalePharmacokineticsUnited StatesConceptsUrinary glucose excretionCanagliflozin 100Type 2 diabetesCanagliflozin 300T2D patientsSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsPharmacodynamics of canagliflozinSingle daily doseCotransporter 2 inhibitorsTreatment of adultsBody mass indexMaximum plasma concentrationPlasma glucose levelsDose-dependent increasePlasma concentration curveDaily doseGlucose excretionPediatric patientsMass indexPlasma concentrationsRenal thresholdGlucose levelsBody weightPatientsRandomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes
Tamborlane WV, Laffel LM, Weill J, Gordat M, Neubacher D, Retlich S, Hettema W, Hoesl CE, Kaspers S, Marquard J. Randomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 640-648. PMID: 29171139, DOI: 10.1111/pedi.12616.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge of OnsetChildDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansLinagliptinMalePlacebosConceptsDPP-4 inhibitionDipeptidyl peptidase-4 inhibitor linagliptinType 2 diabetesInhibitor linagliptinAdult patientsPediatric patientsPlacebo-controlled dose-finding studyDrug-related adverse eventsPrimary efficacy endpointParallel-group studyWeeks of treatmentDose-finding studyDose-dependent reductionEfficacy endpointMean HbA1cAdverse eventsFPG levelsTrough levelsClinical efficacySafety profilePlasma glucosePharmacodynamic endpointsStudy populationPatientsLinagliptinInternational Consensus on Use of Continuous Glucose Monitoring
Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 2017, 40: 1631-1640. PMID: 29162583, PMCID: PMC6467165, DOI: 10.2337/dc17-1600.Peer-Reviewed Original ResearchInitial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry
Bacha F, Cheng P, Gal RL, Kollman C, Tamborlane WV, Klingensmith GJ, Manseau K, Wood J, Beck RW. Initial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry. Hormone Research In Paediatrics 2017, 89: 47-55. PMID: 29131017, DOI: 10.1159/000481687.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBody Mass IndexChildDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansInsulinMaleMetforminRegistriesConceptsMetformin monotherapyType 2 diabetesLower HbA1cGroup 2Shorter diabetes durationYear of diagnosisAdequate controlDiabetes durationT2D durationGlycemic controlInitial presentationMultivariable analysisBMI percentileSuccessful treatmentBACKGROUND/Early diagnosisMonotherapyTherapy highlightGroup 1HbA1cMetabolic controlMetforminDiagnosisGreater likelihoodRapid deteriorationPredictors of Loss to Follow-Up among Children with Type 2 Diabetes
Shoemaker A, Cheng P, Gal RL, Kollman C, Tamborlane WV, Klingensmith GJ, Clements MA, Hannon TS, Heptulla R, Less J, Wood J. Predictors of Loss to Follow-Up among Children with Type 2 Diabetes. Hormone Research In Paediatrics 2017, 87: 377-384. PMID: 28505610, DOI: 10.1159/000475595.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentDiabetes Mellitus, Type 2FemaleFollow-Up StudiesHumansMaleModels, BiologicalPatient ComplianceConceptsType 2 diabetesMultivariable logistic regression modelPediatric diabetes centersPredictors of lossLogistic regression modelsRace/ethnicityClinical factorsDiabetes CenterPoor complianceOdds ratioMedical careEnrollment variablesSignificant predictorsSocioeconomic factorsOlder adolescentsT2DDiabetesPatientsClinicCareRegression modelsParent educationPredictorsYearsFinal model